...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>癌と化学療法 >Case reports of use of TS-1 for second/third-line chemotherapy for advanced colorectal carcinoma
【24h】

Case reports of use of TS-1 for second/third-line chemotherapy for advanced colorectal carcinoma

机译：TS-1用于晚期大肠癌二线/三线化疗的病例报告

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The usefulness of TS-1 as second/third-line therapy was evaluated in 7 patients with stage IIIb/IV colorectal cancer in whom the response to prior 5-FU/l-LV+CPT-11 therapy administered at our hospital had been rated as progressive disease (PD). The initial dose level of TS-1 was set at 80 mg/m2. The median follow-up period was 8 months. The response rate to TS-1 therapy was 14.3% (1/7). Four cases (57.1%) were rated as showing partial response (PR) or no change (NC). The median time to treatment failure (TTF) was 117 days. Thus, relatively satisfactory tumor dormancy was achieved in IFL-resistant cases. All adverse reactions observed were grade 2 or less severe. These results suggest that TS-1 used as the second/third-line therapy will contribute to improving the prognosis of patients with advanced or recurrent colorectal cancer.
机译：在7例IIIb / IV期大肠癌患者中评估了TS-1作为二线/三线治疗的有用性，这些患者已评估了对我院以前接受的5-FU / 1-LV + CPT-11治疗的反应作为进行性疾病（PD）。 TS-1的初始剂量水平设置为80 mg / m2。中位随访期为8个月。 TS-1治疗的缓解率为14.3％（1/7）。有4例（57.1％）被定为显示部分缓解（PR）或无变化（NC）。治疗失败的中位时间（TTF）为117天。因此，在IFL抗性病例中获得了相对令人满意的肿瘤休眠。观察到的所有不良反应均为2级或更严重。这些结果表明，TS-1用作二线/三线治疗将有助于改善晚期或复发性结直肠癌患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号